Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

J Fernando Arevalo, Jans Fromow-Guerra, Hugo Quiroz-Mercado, Juan G. Sanchez, Lihteh Wu, Mauricio Maia, Maria H. Berrocal, Adriana Solis-Vivanco, Michel E. Farah

Research output: Contribution to journalArticle

Abstract

Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P

Original languageEnglish (US)
Pages (from-to)743-750
Number of pages8
JournalOphthalmology
Volume114
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Macular Edema
Visual Acuity
Retina
Fluorescein Angiography
Optical Coherence Tomography
Intravitreal Injections
Injections
Diabetic Retinopathy
Multicenter Studies
Analysis of Variance
Retrospective Studies
Outcome Assessment (Health Care)
Bevacizumab

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up. / Arevalo, J Fernando; Fromow-Guerra, Jans; Quiroz-Mercado, Hugo; Sanchez, Juan G.; Wu, Lihteh; Maia, Mauricio; Berrocal, Maria H.; Solis-Vivanco, Adriana; Farah, Michel E.

In: Ophthalmology, Vol. 114, No. 4, 04.2007, p. 743-750.

Research output: Contribution to journalArticle

Arevalo, JF, Fromow-Guerra, J, Quiroz-Mercado, H, Sanchez, JG, Wu, L, Maia, M, Berrocal, MH, Solis-Vivanco, A & Farah, ME 2007, 'Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up', Ophthalmology, vol. 114, no. 4, pp. 743-750. https://doi.org/10.1016/j.ophtha.2006.12.028
Arevalo, J Fernando ; Fromow-Guerra, Jans ; Quiroz-Mercado, Hugo ; Sanchez, Juan G. ; Wu, Lihteh ; Maia, Mauricio ; Berrocal, Maria H. ; Solis-Vivanco, Adriana ; Farah, Michel E. / Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up. In: Ophthalmology. 2007 ; Vol. 114, No. 4. pp. 743-750.
@article{35ba724d8a204404beb57ed90e25958f,
title = "Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up",
abstract = "Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5{\%}) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7{\%}) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P",
author = "Arevalo, {J Fernando} and Jans Fromow-Guerra and Hugo Quiroz-Mercado and Sanchez, {Juan G.} and Lihteh Wu and Mauricio Maia and Berrocal, {Maria H.} and Adriana Solis-Vivanco and Farah, {Michel E.}",
year = "2007",
month = "4",
doi = "10.1016/j.ophtha.2006.12.028",
language = "English (US)",
volume = "114",
pages = "743--750",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Primary Intravitreal Bevacizumab (Avastin) for Diabetic Macular Edema. Results from the Pan-American Collaborative Retina Study Group at 6-Month Follow-up

AU - Arevalo, J Fernando

AU - Fromow-Guerra, Jans

AU - Quiroz-Mercado, Hugo

AU - Sanchez, Juan G.

AU - Wu, Lihteh

AU - Maia, Mauricio

AU - Berrocal, Maria H.

AU - Solis-Vivanco, Adriana

AU - Farah, Michel E.

PY - 2007/4

Y1 - 2007/4

N2 - Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P

AB - Purpose: To report the 6-month anatomic and best-corrected visual acuity (BCVA) response after primary intravitreal bevacizumab (Avastin) in patients with diabetic macular edema (DME). Design: Interventional retrospective multicenter study at 6 centers from 6 countries of patients with DME. Participants: We reviewed the clinical records of 88 consecutive patients (110 eyes) with DME. Seventy-eight eyes of 64 consecutive patients with a minimum follow-up of 6 months and mean age of 59.7±9.3 years were included in this analysis. Intervention: Patients were treated with at least one intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab and underwent Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Repeated-measures analysis of variance was used to compare mean values. Main Outcome Measures: Changes in BCVA, OCT, and FA. Results: Mean follow-up was 6.31±0.81 months (range, 6-9). Sixteen (20.5%) eyes needed a second injection at a mean of 13.8 weeks (range, 4-28), and 6 eyes needed a third injection (7.7%) at a mean of 11.5 weeks (range, 5-20). The mean baseline BCVA was 0.87 (logarithm of the minimum angle of resolution), and the final mean BCVA was 0.6, a difference that was statistically significant (P

UR - http://www.scopus.com/inward/record.url?scp=33947581702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947581702&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2006.12.028

DO - 10.1016/j.ophtha.2006.12.028

M3 - Article

VL - 114

SP - 743

EP - 750

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 4

ER -